{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:35:38Z","timestamp":1777361738900,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.eururo.2006.06.012","type":"journal-article","created":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T10:30:22Z","timestamp":1153305022000},"page":"207-216","source":"Crossref","is-referenced-by-count":98,"title":["The Efficacy of Drugs for the Treatment of LUTS\/BPH, A Study in 6 European Countries"],"prefix":"10.1016","volume":"51","author":[{"given":"Annie","family":"Hutchison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Berges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remigio Vela","family":"Navarrete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2006.06.012_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2003.10.016","article-title":"Optimising the medical management of benign prostatic hyperplasia","volume":"45","author":"Marberger","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0090-4295(03)00480-1","article-title":"Lower urinary tract symptoms\/benign prostatic hyperplasia: maintaining symptom control and reducing complications","volume":"62","author":"O\u2019Leary","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.06.012_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00120-005-0798-4","article-title":"Drug therapy for benign prostatic hyperplasia. A systematic overview","volume":"44","author":"Berges","year":"2005","journal-title":"Urologe"},{"key":"10.1016\/j.eururo.2006.06.012_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2004.07.016","article-title":"EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)","volume":"46","author":"Madersbacher","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0210-4806(00)72418-1","article-title":"Prostatic benign hypertrophy: review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin","volume":"24","author":"Vela Navarrete","year":"2000","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.eururo.2006.06.012_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.pcan.4500680","article-title":"A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"6","author":"Rigatti","year":"2003","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2006.06.012_bib7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1464-410X.1997.00205.x","article-title":"Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)","volume":"80","author":"Buzelin","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1464-410X.1997.00411.x","article-title":"Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses","volume":"80","author":"Lee","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1442-2042.2000.00175.x","article-title":"Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Benign prostatic hyperplasia","volume":"7","author":"Tsujii","year":"2000","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000052318","article-title":"Clinical pharmacology of alpha1-blockers","volume":"36","author":"Kirby","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2004.05.008","article-title":"On behalf of the ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5\u03b1-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia","volume":"46","author":"Debruyne","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2165\/00002512-199506050-00005","article-title":"Alpha 1-blockers vs 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review","volume":"6","author":"Andersen","year":"1995","journal-title":"Drugs Aging"},{"key":"10.1016\/j.eururo.2006.06.012_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000020246","article-title":"Medical therapy for benign prostatic hyperplasia: a review of the literature","volume":"38","author":"Clifford","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib14","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2006.06.012_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E","article-title":"Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients","volume":"29","author":"Carraro","year":"1996","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2006.06.012_bib16","first-page":"578","article-title":"Combination medical therapy for symptomatic benign prostatic hyperplasia","volume":"5","author":"Savage","year":"1998","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1464-410X.2003.03077.x","article-title":"A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia","volume":"91","author":"Kirby","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.06.012_bib18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1517\/14656566.5.5.1209","article-title":"Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia","volume":"5","author":"Doggrell","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eururo.2006.06.012_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","article-title":"On behalf of the SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5\u03b1-reductase inhibitor dutasteride","volume":"44","author":"Barkin","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000052567","article-title":"Lower urinary tract symptoms suggestive of benign prostatic obstruction \u2013 TRIUMPH: the role of general practice databases","volume":"39","author":"Logie","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0302-2838(03)00376-2","article-title":"Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the TRIUMPH project","volume":"44","author":"Verhamme","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00120-002-0234-y","article-title":"Phytotherapy of benign prostatic hyperplasia. Current evidence-based evaluation","volume":"41","author":"Dreikorn","year":"2002","journal-title":"Urologe (Ausg. A)"},{"key":"10.1016\/j.eururo.2006.06.012_bib23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2004.01.015","article-title":"Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients\u2014PERMAL study subset analysis","volume":"45","author":"Debruyne","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.06.012_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0302-2838(02)00066-0","article-title":"For the members of the PERMAL Study Group. Comparison of a phytotherapeutic agent (Permixon) with an \u03b1-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study","volume":"41","author":"Debruyne","year":"2002","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806007214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806007214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T20:27:31Z","timestamp":1547497651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283806007214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0302283806007214"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2006.06.012","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}